Bio-Path Holdings Pivots to Crypto, Creates New Preferred Stock, and Restarts AML Trials
BPTH has more than doubled off its 52-week low of $0.012 on light trading volume (0.2× avg).
Summary
Bio-Path Holdings disclosed a strategic pivot into crypto, created a highly dilutive Series B Preferred stock, acquired a crypto platform, and restarted AML trials — all while under a going concern warning.
Key Events · Financing and Capital Events · BPTH
-
Series B Preferred Stock Created
Board approved 5,000,000 Series B Preferred shares, each convertible into 1,000 common shares, with voting rights on an as-converted basis. This represents potential dilution of up to 5 billion common shares.
-
Acquisition of Himalaya Technologies
Issued 22,342 Series B Preferred shares (subscription payable) to acquire Himalaya Technologies, a crypto social platform, making it a majority-owned subsidiary. The transaction was valued at $670,260.
-
CEO Receives Preferred Shares
Issued 369 Series B Preferred shares to CEO Vikram Grover for a software platform, valued at $11,069.
-
Strategic Advisory Engagement
Engaged Farrington Capital Group to identify a strategic buyer, partner, or licensor for its biotech assets, with a 60-day exclusivity period.
Analysis · BPTH · Life Sciences
Bio-Path Holdings, a financially distressed biotech with a going concern warning, disclosed a sweeping strategic overhaul. The company created a new Series B Preferred stock with 5 million authorized shares, each convertible into 1,000 common shares — a massive potential dilution for existing holders. It used these shares to acquire Himalaya Technologies, a crypto social platform, and issued shares to its CEO for a software platform. The company also engaged Farrington Capital Group to find a buyer or partner for its biotech assets, restarted Phase 2 AML trials at MD Anderson contingent on paying $355,550.76 in past-due bills, and opened a Coinbase account to manage an AI-driven digital asset treasury. These moves signal a desperate attempt to survive by pivoting into cryptocurrency and blockchain, while the biotech core is shopped or revived with minimal cash. The creation of a super-voting, highly convertible preferred stock and the issuance to insiders and a new subsidiary raise significant governance and dilution concerns.
At the time of this filing, BPTH was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.01 to $0.17. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.